- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Failure
The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.
Medtronic Halts Sale of HVAD System, FDA Issues Warning to Stop New Implants
June 04, 2021
After receiving more than 100 complaints, including some involving death, Medtronic has halted sale of the HeartWare Ventricular Assist Device System and the FDA has issued a warning to clinicians to stop new implants of the device.
Pericardial Fat Volume Helps Predict Incident Heart Failure, Even After Adjustment for Obesity
May 25, 2021
Results of an analysis of the MESA study suggest increased pericardial fat volume was associated with a 2-fold increase in heart failure risk in women and a 53% increase in risk among men.
Analysis Details SGLT2 Inhibitors Benefit Across Heart Failure Subgroups
May 20, 2021
Hear from Deepak Bhatt, MD, MPH, on a systematic review and meta-analysis of SGLT2 inhibitor trials examining the effects of the class on heart failure across multiple subgroups, including those with preserved ejection fraction.
Sotagliflozin Shows Significant Benefit for Heart Failure Across the Spectrum of Ejection Fraction
May 17, 2021
A new analysis of the SCORED and SOLOIST trials suggests sotagliflozin could provide substantial benefit for reducing risk of cardiovascular death and worsening heart failure among patients with HFrEF and HFpEF.
TRANSLATE-HF: Gaps in Care Persist Among Patients with HFrEF and Comorbid CKD
May 16, 2021
Hear from Muthiah Vaduganathan, MD, MPH, as he discusses the results of an analysis of data within the GWTG-HF registry that details gaps in care and management of heart failure patients with comorbid kidney disease.
Increased EPA Levels Linked to Lower Heart Failure Risk in REDUCE-IT Trial
May 15, 2021
Data from post hoc analyses of REDUCE-IT indicate patients with increased on-treatment levels of EPA had a lower risk of heart failure and new hospitalization for heart failure when compared to their counterparts with the lowest on-treatment EPA levels.
PARADISE-MI Fails to Meet Primary Endpoint, But Provides Insight into Effects of Entresto in Acute MI
May 15, 2021
The PARADISE-MI study missed achieving a statistically significant reduction in its primary endpoint, but offers insight into the effects of sacubitril/valsartan in patients with a history of acute MI.
Dapagliflozin (Farxiga) Receives Historic FDA Approval for Chronic Kidney Disease
April 30, 2021
The US FDA announced dapagliflozin (Farxiga) received approval for reducing the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression in a statement on April 30.
Patient Race, Income Play Roles in Likelihood of Receiving SGLT2 Inhibitor Prescription
April 18, 2021
Results of a new study from the University of Pennsylvania demonstrate significant racial inequities exist in access to SGLT2 inhibitor treatment among patients with diabetes in the US.
Preterm Birth Associated with Increased Heart Failure Risk Throughout Adulthood
April 09, 2021
An analysis of nearly 4.2 million patients from a birth registry indicates being born preterm was linked to a significantly higher risk of developing heart failure during childhood and a 42% greater risk of heart failure in adulthood.